From Quartz.

🎥 Video Details 🎥

🌟 About This Video 🌟
Eli Lilly reported Phase 3 results showing its experimental drug retatrutide reduced A1C and body weight in adults with Type 2 diabetes. The Phase 3 trial, TRANSCEND-T2D-1, evaluated retatrutide as an adjunct to diet and exercise in 537 participants. Over 40 weeks, A1C fell by up to 2.0% versus 0.8% with placebo, and the highest 12 mg dose yielded 16.8% average weight loss among completers. The once-weekly triple-agonist targets GLP-1, GIP, and glucagon receptors. Reported adverse events at 12 mg included nausea (26.5%), diarrhoea (22.8%), and vomiting (17.6%), with about 5% discontinuing. The drug is unapproved and limited to trials; fuller results are slated for the American Diabetes Association’s June Scientific Sessions, with more Phase 3 readouts due by 2026. #diabetesresearch #weightloss #elililly #retatrutide #clinicaltrials

🤖 Crafted with Rizzle AI 🤖

This video was created using Rizzle AI, the ingenious no-edit video creation platform, with industry-leading assets from GettyImages and Soundstripe. Elevate your video content with Rizzle AI: https://app.rizzle.com/create

🔔 If you enjoyed this video, don’t forget to like, share, and subscribe! 🔔